Quick Answer
Endometrial cancer is a high-yield NEET PG gynaecological oncology topic — postmenopausal bleeding workup, TVS threshold, Type I vs Type II biology, FIGO 2023 staging, and treatment tiers recur every paper. A 62-year-old obese diabetic postmenopausal woman on tamoxifen with painless PMB and TVS endometrial thickness 14 mm needs a 9-step approach:
- Recognise the pattern — postmenopausal bleeding is endometrial cancer until proven otherwise (10-15 percent malignant)
- Risk factors present — obesity (aromatisation), diabetes, nulliparity, late menopause, tamoxifen (2-3 fold risk)
- TVS first — endometrial thickness greater than 4 mm mandates sampling; this patient has 14 mm
- Sampling — outpatient Pipelle first-line; hysteroscopy with directed biopsy for focal lesions or on tamoxifen
- Classify Type I vs Type II — Type I endometrioid, oestrogen-dependent, PTEN + KRAS + PIK3CA mutations, better prognosis; Type II serous/clear cell, oestrogen-independent, p53 mutations, worse prognosis
- Molecular classification (WHO 2023) — POLE ultramutated (best) / MMR-deficient / p53-abnormal (worst) / NSMP; guides therapy
- FIGO 2023 staging — I confined to uterus (Ia/Ib/Ic), II cervical stromal, III locoregional/nodes, IV distant
- Treatment by stage — hysterectomy + BSO + sentinel LN mapping for low-risk Stage I; add pelvic + para-aortic LN + omentectomy + adjuvant chemoradiation for high-risk; pembrolizumab + lenvatinib for advanced/recurrent
- Fertility preservation — only Stage Ia grade 1 endometrioid, no invasion; medroxyprogesterone + serial biopsies; hysterectomy after childbearing
The case
A 62-year-old obese housewife (BMI 34 kg/m²) presents to the gynaecology outpatient department of a tertiary hospital in Delhi with 6 weeks of vaginal bleeding. She has been postmenopausal for 12 years (last menstrual period at age 50, which was late — average Indian menopausal age is 47 years). The bleeding was initially spotting (light staining on undergarments for 2-3 days at a time) but has progressively increased over the last 2 weeks to sanitary-pad-requiring flow with occasional small clots. She denies pelvic pain, weight loss, or urinary symptoms. There is no history of intercourse-related bleeding.
She is nulliparous — she and her husband tried unsuccessfully to conceive in the first 5 years of marriage. She had menarche at 12 and menopause at 55.
Her past medical history is significant. She was diagnosed with stage II oestrogen-receptor-positive breast cancer of the right breast 3 years ago, treated with breast-conserving surgery, axillary clearance, and adjuvant radiotherapy plus chemotherapy (AC + T regimen). She has been on tamoxifen 20 mg daily for the last 3 years as adjuvant endocrine therapy and has 2 more years planned. Her oncologist has been happy with her progress and last mammogram at 6 months was normal.
She has type 2 diabetes mellitus for 8 years (HbA1c 7.2 on metformin plus glimepiride), hypertension for 6 years (BP 138/86 on amlodipine plus telmisartan), and dyslipidaemia on atorvastatin. She lives in a joint family, is a strict vegetarian, walks 20-30 minutes daily, and has no smoking or alcohol history.
Family history — her mother had colorectal cancer at age 65; a maternal aunt had endometrial cancer at 62; a maternal cousin had ovarian cancer. This raises a red flag for Lynch syndrome (hereditary non-polyposis colorectal cancer / HNPCC).
On examination — appears well, mildly obese, alert. Temperature 37.0°C, pulse 82/min, BP 140/88, RR 16/min, SpO2 98 percent. Height 156 cm, weight 82 kg, BMI 33.7 kg/m² (WHO obesity class 1).
General — no pallor, no lymphadenopathy, no leg oedema, no cachexia.
Abdomen — soft, non-tender, no palpable masses, no ascites on percussion; no organomegaly.
Speculum examination — cervix appears healthy with a clear os and no visible lesions; blood is seen trickling from the os rather than from the cervix or vagina — favouring an intrauterine source. The vagina looks atrophic (thin pale mucosa, loss of rugae).
Bimanual pelvic examination — uterus is anteverted, mobile, and NORMAL SIZED (or slightly enlarged), no adnexal mass palpable, no cervical motion tenderness, no cul-de-sac nodularity.
PAP smear was normal 2 years ago.
The consulting gynaecologist recognises the pattern — postmenopausal bleeding in a woman with multiple risk factors (obesity, diabetes, nulliparity, late menopause, tamoxifen for 3 years, and a family history suggestive of Lynch syndrome) — and initiates the standard PMB workup pathway.
Initial assessment and the time-critical principle
The single most important principle in this case is that all postmenopausal bleeding is endometrial cancer until proven otherwise. While only 10-15 percent of PMB is malignant, that pretest probability is high enough that ALL cases require prompt evaluation with TVS and, if the endometrium is thick, endometrial sampling within 2-4 weeks of presentation. Delays lead to advanced-stage diagnoses and worse outcomes.
Tier 1 investigations (first visit)
- Transvaginal ultrasound (TVS) — endometrial thickness 14 mm (postmenopausal cutoff is 4 mm; well above threshold), heterogeneous echogenicity with a focal thickened region at the fundus and irregular endo-myometrial junction; myometrium appears intact but there is a suggestion of superficial invasion at the fundus; ovaries appear atrophic and normal; no free fluid or adnexal masses
- Endometrial biopsy by outpatient Pipelle — done at the initial visit; tissue sample sent for histopathology
- Given tamoxifen use with a heterogeneous, focally thickened endometrium, an outpatient hysteroscopy with directed biopsy is scheduled if Pipelle is inconclusive
- CBC — Hb 10.8 g/dL (mildly low; mild anaemia from bleeding), WBC 8,200, platelets 320,000
- Random blood glucose — 168 mg/dL; HbA1c 7.4
- Renal function — creatinine 0.9, eGFR 82
- LFT — normal
- PAP smear — reassuring, not diagnostic for endometrial cancer (only 40-50 percent sensitivity)
Tier 2 investigations (staging and molecular)
- MRI pelvis with contrast — depicts myometrial invasion depth (crucial for FIGO Ia vs Ib distinction), cervical stromal invasion (II), adnexal involvement, and pelvic lymph nodes; better tissue characterisation than CT for local disease
- CT chest, abdomen, pelvis — screens for distant metastasis, para-aortic and pelvic lymphadenopathy, peritoneal disease
- CA-125 — non-specific but useful baseline; elevated levels suggest extrauterine spread (adnexal, peritoneal, nodal)
- Molecular pathology — after biopsy confirms malignancy:
- Immunohistochemistry — MMR proteins (MLH1, MSH2, MSH6, PMS2), p53, oestrogen and progesterone receptor status
- MLH1 promoter hypermethylation — if MLH1 loss, differentiates sporadic from Lynch syndrome
- POLE mutation testing — hotspot exonuclease-domain mutations (if institutional availability)
- Genetic counselling given family history — offer germline testing for Lynch syndrome (MSH6 or MLH1 germline mutation)
- Preoperative cardiology work-up — ECG, echo (given diabetes, hypertension, obesity, prior anthracycline exposure from breast-cancer chemotherapy)
Histopathology and molecular workflow
The Pipelle biopsy report reads — "Grade 2 endometrioid adenocarcinoma of the endometrium; focal glandular complexity; no unequivocal myometrial invasion identified in this superficial sample; margins uninformative on a Pipelle."
Immunohistochemistry on the biopsy sample —
- MMR proteins — MSH6 loss with retained MLH1, MSH2, PMS2 → likely Lynch syndrome (MSH6 germline mutation)
- p53 — wild-type pattern
- Oestrogen receptor — positive; progesterone receptor — positive
- Ki-67 — 40 percent
Provisional classification
- Bokhman Type I — endometrioid, oestrogen-dependent, low-intermediate grade
- WHO 2023 molecular subgroup — MMR-deficient (MSH6 loss) — an intermediate-prognosis subgroup that is highly responsive to immunotherapy (immune checkpoint inhibitors)
- Lynch syndrome likely — offered genetic counselling and germline testing for the patient and family
MRI findings
- Anteverted uterus with endometrial thickening 14-16 mm at the fundus
- Focal invasion into the inner half of the myometrium (less than 50 percent) — suggests FIGO Ia in this endometrioid grade 2 tumour
- No cervical stromal invasion
- No adnexal involvement, no pelvic lymphadenopathy, no peritoneal fluid or nodularity
- No para-aortic lymphadenopathy
- No suspicious osseous or hepatic metastasis on CT
Preoperative clinical stage
Endometrioid adenocarcinoma of the endometrium, FIGO 2023 Stage Ia (grade 2, less than 50 percent myometrial invasion), MMR-deficient (MSH6 loss), likely Lynch syndrome, in a 62-year-old obese diabetic on tamoxifen — for surgical staging.
Diagnosis
Endometrial adenocarcinoma (endometrioid Type I, grade 2), FIGO 2023 clinical Stage Ia (less than 50 percent myometrial invasion on MRI, no cervical stromal invasion, no adnexal or nodal involvement), MMR-deficient (MSH6 loss) suggestive of Lynch syndrome, arising in a 62-year-old obese diabetic postmenopausal nulliparous woman with 3 years of tamoxifen exposure for prior ER-positive breast cancer — for total hysterectomy + bilateral salpingo-oophorectomy with sentinel lymph node mapping, formal FIGO surgical staging, adjuvant therapy per final pathology and molecular subgroup, germline Lynch testing with family counselling, and Lynch-related colorectal + urothelial + ovarian surveillance.
Management — surgical staging and stage-tailored therapy
1) Surgery — the cornerstone of Stage I disease
- Total abdominal or laparoscopic/robotic hysterectomy + bilateral salpingo-oophorectomy (TAH-BSO) — standard for all endometrial cancer; minimally invasive route is preferred where expertise available (better recovery, reduced morbidity, non-inferior oncological outcomes — LAP2 trial)
- Sentinel lymph node (SLN) mapping — increasingly the standard of care for apparent Stage I disease (FIRES trial); indocyanine green (ICG) dye injected into the cervix maps to pelvic sentinel nodes; if bilateral SLN identified with negative pathology, full lymphadenectomy can often be avoided (reduces lymphoedema)
- Omentectomy — added for serous, clear cell, and carcinosarcoma histologies (Type II) — this patient with endometrioid does not need it
- Peritoneal washings — routine (no longer changes FIGO stage but tracks tumour burden)
- Frozen section for final grading, invasion depth, and lymphovascular space invasion (LVSI) — informs intraoperative decisions on lymphadenectomy extension
2) Adjuvant therapy — driven by final pathology and molecular subgroup
Low-risk (Stage Ia grade 1-2 endometrioid, no LVSI, no molecular high-risk features) — observation with regular follow-up. No adjuvant.
Intermediate-risk (Stage Ia grade 3 OR Stage Ib grade 1-2 OR LVSI) — vaginal brachytherapy alone provides local control without pelvic irradiation morbidity (PORTEC-2 trial).
High-intermediate to high-risk (Stage Ib grade 3, Stage II, serous, clear cell, carcinosarcoma, p53-abnormal molecular subgroup) — external beam pelvic radiotherapy + vaginal brachytherapy + chemotherapy (carboplatin AUC 5-6 + paclitaxel 175 mg/m² every 3 weeks x 6 cycles).
Stage III-IV — adjuvant chemotherapy (carboplatin + paclitaxel) + external beam RT + surgery where feasible.
MMR-deficient (this patient) — increasing evidence for pembrolizumab or dostarlimab adjuvant therapy in high-risk disease (KEYNOTE-B21, NRG-GY018); the molecular subgroup influences adjuvant selection.
POLE ultramutated — de-escalation of chemotherapy is being explored — very good prognosis regardless of stage.
3) Advanced / recurrent disease
- First-line for MMR-deficient (dMMR/MSI-H) — dostarlimab (approved 2021, based on GARNET trial) — impressive response rates
- First-line for MMR-proficient (pMMR/MSS) — pembrolizumab + lenvatinib (Keynote-775) — combination immunotherapy plus tyrosine kinase inhibitor
- Chemotherapy — carboplatin + paclitaxel remains the backbone; add trastuzumab for HER2-positive serous
- Progestational therapy — well-differentiated recurrent or metastatic endometrioid (medroxyprogesterone or megestrol acetate) — modest response but useful in unfit patients
4) Fertility-preserving option (not applicable for this patient — postmenopausal)
- Reserved for young (less than 40 typically), Stage Ia grade 1 endometrioid with NO myometrial invasion on MRI, no extra-uterine disease, motivated for pregnancy
- Medroxyprogesterone acetate 200-500 mg/day OR levonorgestrel-releasing intrauterine device
- Serial endometrial biopsies every 3 months; complete response 60-80 percent by 6-9 months
- Pregnancy encouraged promptly (assisted reproduction often needed)
- Definitive hysterectomy after childbearing complete OR on any recurrence
5) Lynch syndrome management
- Germline testing — offer testing for MMR gene mutations (MLH1, MSH2, MSH6, PMS2, EPCAM) after genetic counselling
- Surveillance — colonoscopy every 1-2 years starting age 20-25, upper endoscopy every 3-5 years, urinalysis annually, gynaecological (although this patient's uterus and ovaries will be removed) and dermatological surveillance
- Family cascade testing — first-degree relatives offered testing if the proband is positive
- Risk-reducing surgery — TAH-BSO after childbearing complete reduces endometrial and ovarian cancer risk substantially
- Chemoprevention — aspirin (CAPP2 trial) reduces colorectal cancer risk in Lynch syndrome
6) Symptom control and supportive care
- Iron for anaemia
- Glycaemic optimisation (endometrial cancer surgery and radiotherapy both compromise glucose control)
- Cardiology clearance for cumulative anthracycline exposure from prior breast-cancer chemotherapy
- VTE prophylaxis pre- and post-op (obesity + malignancy + surgery = high risk)
- Psychosocial support given the second primary cancer diagnosis
Complications — surgical, oncological, treatment-related
Surgical
- Bleeding, infection, VTE — the classic surgical trio
- Ureter injury — 1-2 percent even in experienced hands, especially in obese patients
- Vault haematoma or infection — vaginal cuff complications
- Wound complications — obesity + diabetes = high risk
Radiation-related
- Acute — cystitis, proctitis, vaginitis, skin reactions
- Chronic — vaginal stenosis, sexual dysfunction, radiation cystitis with haematuria, radiation proctitis, small-bowel obstruction, secondary malignancy (rare)
Chemotherapy-related
- Acute — myelosuppression, nausea/vomiting, peripheral neuropathy from paclitaxel (especially in diabetics), hypersensitivity to carboplatin (cumulative risk)
- Long-term — chronic peripheral neuropathy, cognitive changes, fatigue
Recurrent and metastatic
- Recurrence 10-15 percent overall for Stage I; higher for high-grade or Type II; most recur in the first 3 years
- Distant sites — lungs (most common), liver, bone, brain
- Vaginal apex recurrence — most amenable to salvage RT if not previously irradiated
Long-term
- Lymphoedema — from pelvic lymphadenectomy; reduced by SLN-only approach
- Menopausal symptoms — accelerated in premenopausal patients undergoing BSO; HRT is generally CONTRAINDICATED after endometrial cancer (would fuel any residual disease), so non-hormonal management of vasomotor symptoms is used
- Second primary cancers — Lynch syndrome carriers have lifetime risk of colorectal, endometrial, ovarian, urothelial, small bowel, and sebaceous cancers
India-specific considerations
- Rising incidence — parallels India's obesity, diabetes, and delayed-childbearing epidemic; endometrial cancer incidence has risen substantially in the last decade in urban tertiary registries
- Late presentation — cultural taboo around vaginal bleeding, cost, and access lead to Stage III-IV presentations more commonly than in the West; PMB warning-sign awareness is a public health need
- PMJAY (Ayushman Bharat) — covers oncological packages including hysterectomy, radiotherapy, and chemotherapy; targeted therapies (pembrolizumab, dostarlimab, lenvatinib) may need private cover or manufacturer access programmes
- Regional cancer centres (RCC) — Tata Memorial (Mumbai), AIIMS (Delhi), CMC (Vellore), Kidwai (Bangalore), Cachar (Silchar), plus 27 other RCCs — nodal referral for advanced disease
- Lynch syndrome underdiagnosed — universal MMR IHC testing on all endometrial cancer specimens (as recommended by NCCN and increasingly by Indian guidelines) is not yet routine outside tertiary centres; family cascade testing is limited by cost and awareness
- Robotic and minimally invasive surgery — expanding in Indian tertiary centres for endometrial cancer with excellent oncological and recovery outcomes
- Tamoxifen follow-up — women on tamoxifen for breast cancer number in the hundreds of thousands in India; awareness of PMB as an alarm symptom must be reinforced at every oncology visit
- Sentinel LN mapping — increasingly adopted in Indian tertiary centres; ICG availability has improved
- HRT after endometrial cancer — traditionally avoided; individual decisions in low-risk early-stage after full recovery are increasingly considered with multidisciplinary discussion
How NEET PG tests endometrial cancer
Eight recurring patterns.
Pattern 1 — The PMB workup question: Postmenopausal bleeding + TVS endometrial thickness greater than 4 mm → endometrial biopsy (Pipelle first-line; hysteroscopy + directed biopsy for focal lesions).
Pattern 2 — The risk factor question: Unopposed oestrogen — obesity (aromatisation), PCOS, nulliparity, early menarche/late menopause, tamoxifen (2-3 fold), unopposed HRT, Lynch syndrome (40-60 percent lifetime risk).
Pattern 3 — The Type I vs Type II question: Type I = endometrioid, oestrogen-dependent, PTEN + KRAS + PIK3CA, better prognosis. Type II = serous/clear cell, oestrogen-independent, p53, worse prognosis.
Pattern 4 — The molecular classification question: POLE ultramutated (best), MMR-deficient (intermediate, immunotherapy responsive), p53 abnormal (worst), NSMP (heterogeneous).
Pattern 5 — The FIGO 2023 staging question: Stage I confined to uterus (Ia less than 50 percent, Ib greater than or equal to 50 percent, Ic aggressive histology), II cervical stromal, III locoregional/nodes (IIIc1 pelvic, IIIc2 para-aortic), IV distant.
Pattern 6 — The treatment tier question: Low-risk Stage I — TAH-BSO + SLN mapping; high-risk Stage I / Stage II — add adjuvant chemoradiation; Stage III-IV — chemotherapy + RT + surgery when feasible; advanced/recurrent — pembrolizumab + lenvatinib (pMMR) or dostarlimab (dMMR).
Pattern 7 — The fertility preservation question: Only Stage Ia grade 1 endometrioid, no myometrial invasion — medroxyprogesterone + 3-monthly biopsies; hysterectomy after childbearing.
Pattern 8 — The Lynch syndrome question: MMR-deficient endometrial cancer in a young woman with family cancer history → germline testing for MLH1/MSH2/MSH6/PMS2/EPCAM.
High-yield one-liners
- All PMB is endometrial cancer until proven otherwise
- TVS endometrial thickness less than 4 mm has NPV over 99 percent in PMB
- Pipelle biopsy is first-line; hysteroscopy for focal lesions
- Tamoxifen increases endometrial cancer risk 2-3 fold; higher Type II proportion
- No routine TVS screening on tamoxifen in asymptomatic women
- Type I = endometrioid, oestrogen-dependent, PTEN/KRAS/PIK3CA
- Type II = serous/clear cell, p53, worse prognosis
- POLE = best prognosis; p53-abnormal = worst
- Omentectomy for serous, clear cell, carcinosarcoma
- SLN mapping is the standard of care in apparent Stage I
- Fertility preservation only for young Stage Ia grade 1 with no invasion
- Lynch syndrome — universal MMR IHC on endometrial cancer; cascade testing
Frequently Asked Questions
What is the workup approach for postmenopausal bleeding and what does an endometrial thickness of greater than 4 mm mean?
Postmenopausal bleeding (PMB) is defined as any vaginal bleeding at least 12 months after the last menstrual period; it is endometrial cancer until proven otherwise, though only 10-15 percent of PMB is malignant — the rest is endometrial atrophy (60-70 percent), endometrial polyp, endometrial hyperplasia, submucous fibroid, cervical or vaginal atrophy, hormone therapy effect, or, rarely, cervical or vaginal cancer. First-line evaluation is transvaginal ultrasound (TVS) to measure endometrial thickness. A postmenopausal endometrial thickness of 4 mm or less has a very high negative predictive value (over 99 percent) for endometrial cancer in women with PMB — expectant management with reassessment on recurrence is acceptable. An endometrial thickness greater than 4 mm mandates endometrial tissue sampling — outpatient Pipelle aspiration is the first-line (well tolerated, ~90 percent sensitivity for endometrial cancer if the endometrium is diffusely thickened, cost-effective), hysteroscopy with directed biopsy is the gold standard for focal lesions such as polyps and where Pipelle is insufficient or inconclusive, and dilatation-and-curettage (D&C) is reserved for cases where outpatient sampling fails. For asymptomatic postmenopausal women with an incidental TVS finding of thick endometrium the threshold is context-dependent — many guidelines only intervene if greater than 11 mm without bleeding. NEET PG most commonly tests the 4 mm threshold WITH bleeding and the Pipelle-first, hysteroscopy-for-focal-lesions algorithm.
How do Type I and Type II endometrial cancers differ biologically and prognostically?
The Bokhman classification splits endometrial cancer into two distinct clinicopathological types. Type I (80 percent of cases) is endometrioid histology, oestrogen-dependent, arising on a background of unopposed oestrogen exposure (obesity via peripheral aromatisation of androgens, PCOS, nulliparity, early menarche, late menopause, tamoxifen, HRT with unopposed oestrogen), typically presents in perimenopausal or early postmenopausal women, is preceded by atypical hyperplasia (now called endometrial intraepithelial neoplasia, EIN), is usually low grade at diagnosis with better prognosis (5-year survival 80-95 percent for early stage), and carries PTEN, KRAS, and PIK3CA mutations. Type II (20 percent) is non-endometrioid (serous, clear cell, carcinosarcoma), oestrogen-independent, arises in an atrophic endometrium in older women, is preceded by serous endometrial intraepithelial carcinoma (SEIC), is high grade at diagnosis with poorer prognosis (5-year survival 20-50 percent even for early stage), and carries p53 mutations. The 2023 WHO molecular classification refines this into 4 subgroups — POLE ultramutated (best prognosis, chemotherapy may be de-escalated), MMR-deficient/MSI-high (intermediate, immunotherapy responsive), p53 abnormal (worst, aggressive adjuvant), and NSMP (no specific molecular profile, heterogeneous). NEET PG has begun to test the molecular classification directly since 2022-2023.
What is the FIGO 2023 staging system for endometrial cancer and how does treatment vary by stage?
FIGO 2023 substantially revised endometrial cancer staging to incorporate histology, myometrial invasion, LVSI, and molecular subgroup. Stage I — confined to the uterus (Ia less than 50 percent myometrial invasion in a low-grade endometrioid tumour, Ib greater than or equal to 50 percent invasion, Ic includes aggressive histologies such as high-grade serous or clear cell or carcinosarcoma even without deep invasion). Stage II — cervical stromal invasion. Stage III — locoregional spread — IIIa uterine serosa or adnexa, IIIb vaginal or parametrial, IIIc lymph node spread (IIIc1 pelvic, IIIc2 para-aortic). Stage IV — distant — IVa bladder or bowel mucosal, IVb peritoneal metastasis, IVc distant metastasis. Treatment principles — Stage I low-grade endometrioid (Ia, Ib grade 1-2): total hysterectomy with bilateral salpingo-oophorectomy (BSO) with or without sentinel lymph node mapping; adjuvant vaginal brachytherapy for select intermediate risk. Stage I high-risk (Ic, grade 3, serous, clear cell): hysterectomy + BSO + full pelvic and para-aortic lymphadenectomy + omentectomy for serous or clear cell + adjuvant chemotherapy (carboplatin + paclitaxel) + external beam RT and/or vaginal brachytherapy. Stage II: modified radical hysterectomy in select cases + adjuvant chemoradiation. Stage III-IV: chemotherapy (carboplatin + paclitaxel) + external beam RT + surgery if feasible. Recurrent or advanced disease — pembrolizumab + lenvatinib (for MMR-proficient) or dostarlimab (for MMR-deficient); progestational therapy for well-differentiated recurrent disease. Fertility-preservation for select young Stage Ia grade 1 endometrioid with no myometrial invasion — medroxyprogesterone acetate + monitoring biopsy every 3 months; hysterectomy after childbearing complete.
Why is tamoxifen a risk factor for endometrial cancer and how do you counsel about it?
Tamoxifen is a selective oestrogen receptor modulator (SERM) with tissue-specific effects — an oestrogen ANTAGONIST at the breast (its therapeutic role in ER-positive breast cancer) but a partial oestrogen AGONIST at the endometrium and bone. This paradoxical endometrial oestrogen agonist activity increases the risk of endometrial polyps, endometrial hyperplasia, and endometrial cancer approximately 2-3 fold over baseline in postmenopausal women, with the risk starting to rise after 2 years of use and persisting for years after cessation. Importantly, tamoxifen-associated endometrial cancers include a higher proportion of high-grade Type II serous and mixed histologies with worse prognosis than the general population. Counselling — women on tamoxifen for breast cancer should be told about postmenopausal bleeding as an alarm symptom requiring urgent gynaecology review; there is NO evidence for routine annual TVS or endometrial biopsy screening in ASYMPTOMATIC women because sensitivity and specificity are poor and false-positive rates lead to unnecessary procedures. Prompt evaluation of any bleeding is the standard — TVS may be difficult to interpret (tamoxifen can cause subendometrial cystic changes mimicking hyperplasia), so hysteroscopy with directed biopsy is often preferred over Pipelle. In premenopausal women on tamoxifen, endometrial cancer risk is not significantly elevated. NEET PG tests the 2-3 fold risk increase, the higher Type II proportion, and the symptomatic-evaluation-only screening principle.
When is fertility-preservation surgery an option in endometrial cancer and how is it managed?
Fertility-preserving management is an option for a very carefully selected subset of young women with endometrial cancer who wish to preserve childbearing potential. Strict eligibility criteria — (1) age less than 40 (some centres go up to 45), (2) Stage Ia grade 1 endometrioid histology confirmed by expert pathology review of the endometrial biopsy, (3) NO myometrial invasion on MRI (the ideal preoperative imaging), (4) NO extrauterine disease on MRI or CT, (5) NO contraindication to progestational therapy, (6) motivated patient with clear understanding of the trade-offs and follow-up burden, and (7) desire for pregnancy in the near term. Treatment — medroxyprogesterone acetate 200-500 mg/day orally OR megestrol acetate OR levonorgestrel intrauterine device (which delivers high-dose local progestin without systemic side effects and is increasingly first-line). Response monitoring — endometrial biopsy every 3 months; complete response rates are 60-80 percent by 6-9 months. Once complete response is documented, encourage pregnancy promptly (assisted reproduction may be needed); definitive hysterectomy is recommended after childbearing complete OR at first evidence of recurrence. Recurrence rates are 25-40 percent even after complete response, and progressive disease during observation is a devastating outcome — this is why comprehensive counselling and expert oncogynaecology centre management are essential. NEET PG asks the eligibility criteria (Ia grade 1, no invasion, no extra-uterine disease), the medroxyprogesterone therapy, and the mandatory follow-up plus definitive surgery.
This content is for educational purposes for NEET PG exam preparation. It is not a substitute for professional medical advice, diagnosis, or treatment. Clinical information has been reviewed by qualified medical professionals.
Written by: NEETPGAI Editorial Team
Reviewed by: Pending SME Review
Last reviewed: July 2026
